Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

Exclusion Criteria

• •Patients must not have any serious uncontrolled acute or chronic medical condition that would interfere with this treatment. Examples would include active acute or chronic infection requiring antibiotics, uncontrolled cardiovascular, endocrine, or infectious disease.
• •Patients must not have significant ongoing cardiac problems, myocardial infarction within the last six months, uncontrolled hypertension, unstable angina, uncontrolled arrhythmia or congestive heart failure.
• •Surgery less than or equal to 14 days prior to study registration
• •Patients who have had prior radiation or chemotherapy in which the last treatment administration is less than or equal to 28 days prior to registration. Patients who have had prior treatment with ipilimumab or Interleukin-2 will be allowed as long as this 28 day wash-out period is followed.
• •Patients who are breast feeding or have a positive pregnancy test (if female).
• •Due to the possibility of harm to a fetus or nursing infant from this treatment regimen, patients must not be pregnant or nursing. Women and men of reproductive potential must have agreed to use an effective contraceptive method.
• •No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years.